Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335284 | 0.79 | DRD2 (0.55) | CHRM1CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL11343143 | 0.79 | HDAC3 (0.60) | NPC1ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4509670 | 0.79 | CHRM1 (0.72) | CHRM1CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL5345293 | 0.78 | CHRM1 (0.62) | CHRM1CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL251270 | 0.78 | ACHE (0.65) | HTR1ADRD2DRD4ACHEHTR4 | |
| SCHEMBL4510566 | 0.78 | CHRM1 (0.74) | CHRM1CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL5335803 | 0.77 | DRD2 (0.61) | CHRM1CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL4489441 | 0.77 | DRD2 (0.77) | CHRM1CHRM2CHRM4HTR1ACHRM5 | |
| SCHEMBL9046068 | 0.77 | HDAC3 (0.58) | ALDH1A1SMN1; SMN2HDAC3 | |
| SCHEMBL7381022 | 0.76 | MMP13 (0.54) | HTR1ADRD2SLC6A2SLC6A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | claimed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | claimed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| US-20070155795-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7238713-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1535912-A1 | Muscarinic agonists | Arcadia Pharmaceuticals Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | disclosed |
| EP-1278741-B1 | MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6627645-B2 | Cholinergic agents | ACADIA PHARMACEUTICALS, INC. | 2003-09-30 | — | — | US | disclosed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | CHRM1 2/4885CHRM2 1/4885CHRM4 3/4885 |
| US-20070155795-A1 | MUSCARINIC AGONISTS | CHRM2, CHRM1, CHRM4 | CHRM1 2/4885CHRM2 1/4885CHRM4 3/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | CHRM1 2/4885CHRM2 1/4885CHRM4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.